TY - JOUR
T1 - Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment
AU - Augustine, Christina K.
AU - Yoshimoto, Yasunori
AU - Gupta, Mukur
AU - Zipfel, Patricia A.
AU - Selim, M. Angelica
AU - Febbo, Phillip
AU - Pendergast, Ann Marie
AU - Peters, William P.
AU - Tyler, Douglas S.
PY - 2008/5/15
Y1 - 2008/5/15
N2 - Malignant transformation in melanoma is characterized by a phenotype "switch" from E- to N-cadherin, which is associated with increased motility and invasiveness of the tumor and altered signaling, leading to decreased apoptosis. We hypothesized that the novel pentapeptide (ADH-1), which disrupts N-cadherin adhesion, could sensitize melanoma tumors to the cytotoxic effects of chemotherapy. N-cadherin-expressing human melanoma-derived cell lines were used to generate xenografts in animal models to study isolated limb infusion with melphalan and systemic chemotherapy with temozolomide. We report here that melphalan in combination with ADH-1 significantly reduced tumor growth up to 30-fold over melphalan alone. ADH-1 enhancement of response to melphalan was associated with increased formation of DNA adducts, increased apoptosis, and intracellular signaling changes associated with focal adhesions and fibroblast growth factor receptors. Targeted therapy using an N-cadherin antagonist can dramatically augment the antitumor effects of chemotherapy and is a novel approach to optimizing treatment for melanoma.
AB - Malignant transformation in melanoma is characterized by a phenotype "switch" from E- to N-cadherin, which is associated with increased motility and invasiveness of the tumor and altered signaling, leading to decreased apoptosis. We hypothesized that the novel pentapeptide (ADH-1), which disrupts N-cadherin adhesion, could sensitize melanoma tumors to the cytotoxic effects of chemotherapy. N-cadherin-expressing human melanoma-derived cell lines were used to generate xenografts in animal models to study isolated limb infusion with melphalan and systemic chemotherapy with temozolomide. We report here that melphalan in combination with ADH-1 significantly reduced tumor growth up to 30-fold over melphalan alone. ADH-1 enhancement of response to melphalan was associated with increased formation of DNA adducts, increased apoptosis, and intracellular signaling changes associated with focal adhesions and fibroblast growth factor receptors. Targeted therapy using an N-cadherin antagonist can dramatically augment the antitumor effects of chemotherapy and is a novel approach to optimizing treatment for melanoma.
UR - http://www.scopus.com/inward/record.url?scp=45549085493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45549085493&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-07-5949
DO - 10.1158/0008-5472.CAN-07-5949
M3 - Article
C2 - 18483261
AN - SCOPUS:45549085493
SN - 0008-5472
VL - 68
SP - 3777
EP - 3784
JO - Cancer Research
JF - Cancer Research
IS - 10
ER -